Vol. 8, 2023

Pharmaceutical Sciences

VACCINE PROPHYLAXIS AS THE KEY TO SUCCESS AGAINST POLIOMIELYTIS

Jasmina Jovanović Mirković , Milica Stanojević, Christos Alexopoulos, Bojana Miljković, Marko Jovanović, Dragana Đorđević Šopalović

Pages: 36-39

DOI: 10.37392/RapProc.2023.08

Poliomyelitis (lat. acute anterior poliomyelitis, Henne-Medin’s disease) is an acute infectious disease caused by Poliovirus (types 1, 2 and 3). The disease most often occurs in childhood, either individually or in epidemics. The routes of transmission of the infection are the oral-fecal route. The infection can occur without any symptoms or as a general infection, such as meningitis or paralysis. The clinical picture of the disease shows the appearance of several stages: the pre-lytic stage, the paralysis stage and the recovery stage. The fastest way to confirm the diagnosis is to prove viral RNA by PCR in stool, blood or cerebrospinal fluid. There are also serological neutralization tests. During the acute phase, symptomatic and supportive therapy is carried out, and after the acute phase, active physical therapy and rehabilitation are carried out in more severe forms of the disease. Today, this disease is very rare, thanks to systemic active immunization. Primary immunization against poliomyelits (polio) is in the first year of life with three doses of pentavalent Pentaxim vaccine, six weeks apart, and revaccinations are carried out according to the mandatory vaccination calendar in the second, seventh and fourteenth years of life. The vaccine given in multiple doses provides protection throughout life. The aim of this paper is to compare the results of successfully implemented vaccine prophylaxis at the level of primary health care for the territory of the Pomoravlje District in Serbia in the period from 2008-2012. Results and discussion. Based on the Report on Immunization against Poliomyelitis in the Pomoravlje District in the period 01.01.2011 - 31.12.2011, it was noted that by far the largest number of persons vaccinated with the OPV vaccine was in the municipalities of Despotovac, Paracin, Rekovac and Svilajnac, where the percentage of those vaccinated was 100%. Based on the data, it can be seen that the smallest response of children was in the territory of the municipality of Cuprija (81.36%). Statistical data processing in the SPSS Statistics 20 showed that the third revaccination carried out at the age of 14 has a statistical significance of p<0.05, χ2=14.02 at the level of the city of Despotovac for the calendar year 2012. compared to the five-year period from 2008-2012. Conclusion. Based on the statistically processed results, a high level of coverage and high success rate of the implemented vaccination for the five-year period from 2008-2012 was observed for the territory of the Pomoravlje District. The key to success in the fight against infectious diseases is reflected in the implementation of mandatory immunizations according to the vaccination calendar prescribed by each country and is considered one of the best ways to reduce morbidity, eliminate, even eradicate infectious diseases.
  1. P. E. Sartwell, “The incubation period of poliomyelitis,” Am. J. Public Health Nations Health , vol. 42, no. 11, pp. 1403 – 1408, Nov. 1952.
    DOI: 10.2105/ajph.42.11.1403
    PMid: 12986020
    PMCid: PMC1525998
  2. V. R. Racaniello, “One hundred years of poliovirus pathogenesis,” Virology , vol. 344, no. 1, pp. 9 – 16, Jan. 2006.
    DOI: 10.1016/j.virol.2005.09.015
    PMid: 16364730
  3. J. R. Paul, D. M. Horstmann, “A survey of poliomyelitis virus antibodies in French Marocco,” Am. J. Trop. Med. Hyg., vol. 4, no. 3, pp. 512 – 524, May 1955.
    DOI: 10.4269/ajtmh.1955.4.512
    PMid: 14376777
  4. A. B. Sabin et al., “Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses,” JAMA, vol. 173, no. 14, pp. 1521 – 1526, Aug. 1960.
    DOI: 10.1001/jama.1960.03020320001001
    PMid: 14440553
  5. A. B. Sabin, “Present position of immunization against poliomyelitis with live virus vaccines,” Br. Med. J., vol. 1, no. 5123, pp. 663 – 680, Mar. 1959.
    DOI: 10.1136/bmj.1.5123.663
    PMid: 13629086
    PMCid: PMC1993129
  6. R. N. Basu, “Magnitude of problem of poliomyelitis in India,” Indian Pediatr. , vol. 18, no. 8, pp. 507 – 511, Aug. 1981.
    PMid: 7309212
  7. S. Mueller, E. Wimmer, J. Cello, “Poliovirus and poliomyelitis: a tale of guts, brains, and an accidental event,” Virus Res., vol. 111, no. 2, pp. 175 – 193, Aug. 2005.
    DOI: 10.1016/j.virusres.2005.04.008
    PMid: 15885840
  8. J. E. Salk et al., “Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines,” Am. J. Public Health Nations Health, vol. 44, no. 5, pp. 563 – 570, May 1954.
    DOI: 10.2105/ajph.44.5.563
    PMid: 13148396
    PMCid: PMC1620937
  9. A. J. Mohammed et al., “Fractional doses of inactivated poliovirus vaccine in Oman,” N. Engl. J. Med., vol. 362, no. 25, pp. 2351 – 2359, Jun. 2010.
    DOI: 10.1056/NEJMoa0909383
    PMid: 20573923
  10. D. L. Heymann, R. W. Sutter, R. B. Aylward, “A vision of a world without polio: the OPV cessation strategy,” Biologicals, vol. 34, no. 2, pp. 75 – 79, Jun. 2006.
    DOI: 10.1016/j.biologicals.2006.03.005
    PMid: 16682224
  11. D. A. Gust et al., “Parent attitudes toward immunizations and healthcare providers the role of information,” Am. J. Prev. Med., vol. 29, no. 2, pp. 105 – 112, Aug. 2005.
    DOI: 10.1016/j.amepre.2005.04.010
    PMid: 16005806
  12. B. Abbotts, L. M. Osborn, “Immunization status and reasons for immunization delay among children using public health immunization clinics,” Am. J. Dis. Child., vol. 147, no. 9 , pp. 965 – 968, Sep. 1993.
    DOI: 10.1001/archpedi.1993.02160330055018
    PMid: 8362813
  13. Global poliomyelitis eradication by the year 2000 - plan of action. Global Programme for Vaccines and Immunization. Expanded Programme on Immunization, WHO, Geneva, Switzerland, 1996.
    Retrieved from: https://apps.who.int/iris/bitstream/handle/10665/63160/WHO_EPI_GEN_96.03.pdf?sequence=1&isAllowed=y
    Retrieved on: May 20, 2023
  14. W. Atkins, S. Wolfe, J. Hamborsky, “Poliomyelitis,”inEpidemiology and Prevention of Vaccine-Preventable Diseases, 12th ed., Washington DC, USA: Public Health Foundation, 2012, pp. 249 – 262.
    Retrieved from: https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/table-of-contents.pdf
    Retrieved on: May 20, 2023
  15. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper , WER8523, WHO, Geneva, Switzerland, 2010, pp. 213 – 228.
    Retrieved from: https://www.who.int/publications/i/item/WER8523
    Retrieved on: May 20, 2023
  16. B. Guyer, N. Hughart, “Increasing childhood immunization coverage by improving the effectiveness of primary health care systems for children,” Arch. Pediatr. Adolesc. Med., vol. 148, no. 9, pp. 901 – 902, Sep. 1994.
    DOI: 10.1001/archpedi.1994.02170090015001
    PMid: 8075731
  17. L. Roberts, “Polio eradication. Looking for a little luck,” Science , vol. 323, no. 5915, pp. 702 – 705, Feb. 2009.
    DOI: 10.1126/science.323.5915.702
    PMid: 19197035
  18. R. B. Aylward et al., “Disease eradication as a public health strategy: a case study of poliomyelitis eradication,” Bull. World Health Organ., vol. 78, no. 3, pp. 285 – 297, 2000.
    PMid: 10812724
    PMCid: PMC2560720
  19. K. M. Thompson, R. J. Tebbens, “Eradication versus control for poliomyelitis: an economic analysis,” Lancet,vol. 369, no. 9570, pp. 1363 – 1371, Apr. 2007.
    DOI: 10.1016/S0140-6736(07)60532-7
    PMid: 17448822